Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Centene Corp (CNC) vs Xylem, Inc. (XYL) Price & Performance

Centene CorpTrade
Xylem, Inc.Trade

Price performance (Past 24H)

Key statistics

Centene Corp vs Xylem, Inc. — how do they compare? Centene Corp trades at $66.17 (market cap $32.05B), while Xylem, Inc. trades at $121.1 (market cap $28.76B). The key difference: Centene Corp and Xylem, Inc. are close in size by market cap, and Xylem, Inc. pays a 1.4% dividend while Centene Corp pays none. Which is the better fit depends on your goals.

CNCXYL
Market Cap
$32.05B$28.76B
Sector
HealthIndustrials
52-Week High
$68.72$152.95
52-Week Low
$26.17$106.34
Enterprise Value
$21.10B$30.54B
Dividend Yield
1.4%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Centene Corp

Centene (CNC) trades at $66.56, up 1.2% today, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $71.00. The company reported strong Q2 2026 earnings of $2.51 per share, beating estimates, and raised its full-year EPS guidance, reflecting margin recovery and cost discipline. Revenue growth remains robust, projected to reach $202.9 billion in 2026, though net income margins are negative due to elevated medical costs.

The stock presents a value opportunity with low P/E (8.06) and P/S (0.16) ratios, but investors face risks from Medicaid membership volatility and regulatory pressures. Analyst sentiment is strongly bullish (61% buy ratings), with institutional interest growing, as seen in recent fund additions. Near-term upside is likely if cost controls sustain profitability improvements.

Xylem, Inc.

Xylem (XYL) trades at $121.19, up 0.72% today, with a bullish technical trend and strong fundamental performance. The company reported Q2 2026 EPS of $1.46, beating estimates, and raised full-year profit guidance. Revenue growth is steady, with a net income margin of 11.15% in 2025. Recent acquisitions, like Cornell Pump and Roper Pump, aim to strengthen its industrial water technology presence. The stock shows bullish moving averages but a neutral RSI, with key resistance at $123.

Outlook remains positive due to earnings beats, margin expansion, and strategic acquisitions. Risks include execution of integration and macroeconomic pressures. Analyst consensus is a buy with a $150.43 price target, implying significant upside. Institutional activity is mixed, with some funds increasing stakes while others reduced holdings.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Centene Corp

Centene is a managed-care organization focused on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. Centene served 22 million medical members as of September 2021, mostly in Medicaid (68% of membership), the individual exchanges (10%), Medicare Advantage (6%), and the balance in Tricare (West region), correctional facility, and international plans. The company also serves 4 million users through the Medicare Part D pharmaceutical program.

Read more on CNC

About Xylem, Inc.

Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $6.2 billion in revenue and $611 million in adjusted operating income in 2021.

Read more on XYL